mebendazole Cancer Research Results

Mebendazole — a synthetic benzimidazole anthelmintic drug with emerging drug-repurposing interest in oncology. It is conventionally used against gastrointestinal helminths and acts pharmacologically through β-tubulin binding and disruption of microtubule assembly. In mammalian cancer models, this same microtubule-targeting activity produces mitotic spindle disruption, G2/M arrest and apoptosis. Standard abbreviations are MBZ and MZ. Mebendazole is FDA-approved as an antiparasitic drug but is not approved as an anticancer therapy. Its oncology development is constrained by extremely poor aqueous solubility, highly variable oral systemic exposure and formulation/polymorph-dependent bioavailability.

Primary mechanisms (ranked):

1. β-tubulin binding and microtubule depolymerization, producing abnormal mitotic spindles and G2/M arrest.
2. Intrinsic apoptotic signaling with mitochondrial dysfunction, cytochrome-c release and caspase activation.
3. Suppression of angiogenesis and hypoxic adaptation, including VEGF and HIF-1α/HIF-2α signaling in responsive models.
4. ROS elevation with downstream JAK2/STAT3 suppression in some tumor types.
5. Hedgehog pathway inhibition through disruption of primary-cilium-dependent signaling.
6. Interference with DNA-damage-response trafficking and consequent radiosensitization.
7. Context-dependent inhibition of oncogenic kinase signaling, including BRAF/MEK/ERK-related signaling.

Bioavailability / PK relevance: Oral bioavailability is low and highly variable because mebendazole is poorly water-soluble and undergoes substantial first-pass disposition. Systemic exposure can increase with food, particularly a fatty meal. Crystal polymorphism is important: polymorph C generally has superior dissolution and pharmaceutical performance compared with polymorph A, while formulations designed to improve solubility can substantially increase exposure. These PK limitations are particularly important for oncology because sustained systemic exposure is required, unlike treatment of many intestinal helminth infections.
-bioavailability improves when taken with high fat meal

In-vitro vs systemic exposure relevance: Many cancer-cell effects occur at submicromolar to low-micromolar concentrations, including tubulin disruption and apoptosis. Such concentrations may be approached in some high-dose or optimized-formulation settings, but systemic exposure after conventional antiparasitic dosing is variable and generally much lower and less predictable. Therefore, anticancer activity demonstrated in vitro should not be assumed to occur with standard antiparasitic dosing. Formulation, food intake, polymorph, dose and interpatient PK variability are major translational variables.
-Mebendazole presents a substantially greater documented toxicity concern for the liver than for the kidneys, particularly when used at the high doses and prolonged durations investigated for cancer treatment.

Clinical evidence status: Predominantly preclinical with early human oncology evidence. Phase I studies in adult and pediatric high-grade glioma demonstrate feasibility of substantially higher and prolonged dosing than standard anthelmintic treatment, with hepatic and hematologic toxicity becoming relevant at high exposure. A small randomized placebo-controlled study in metastatic colorectal cancer reported improved response and progression-free survival when mebendazole was added to bevacizumab/FOLFOX4, but the study enrolled only 40 patients and requires independent confirmation. A randomized phase II recurrent-glioblastoma study combining mebendazole with temozolomide or lomustine did not reach its predefined efficacy benchmark. Mebendazole should therefore be classified as an investigational repurposed anticancer adjunct rather than an established cancer therapy.

Mebendazole Cancer Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr